share_log

Cell MedX Corp. Announces Resignation of Director

Cell MedX Corp. Announces Resignation of Director

Cell MedX Corp. 宣佈董事辭職
newsfile ·  02/29 05:47

Vancouver, British Columbia--(Newsfile Corp. - February 28, 2024) - Cell MedX Corp. (OTC Pink: CMXC) ("Cell MedX", or the "Company") a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote anti-aging and general wellness, announces the resignation of Brad Hargreaves from the Board of Directors of the Company.

不列顛哥倫比亞省溫哥華--(Newsfile Corp.-2024 年 2 月 28 日)- Cell MedX Corp.(場外交易粉紅:CMXC) (“Cell MedX” 或 “公司”)是一家專注於促進抗衰老和全身健康的治療和非治療產品的發現、開發和商業化的生物技術公司,宣佈布拉德·哈格里夫斯辭去公司董事會的職務。

The resignation of Mr. Hargreaves was not due to any disagreement with the Company on any matter relating to the Company's operations, policies or practice or otherwise. Cell MedX has not filled the vacancy created by the resignation of Mr. Hargreaves as a member of the Board of Directors.

哈格里夫斯先生之所以辭職,並不是因爲在與公司運營、政策或做法或其他有關的任何問題上與公司存在任何分歧。Cell MedX尚未填補因哈格里夫斯辭去董事會成員職務而產生的空缺。

The Company would like to thank Mr. Hargreaves for his contribution to the development of the Company and wishes him the best of success in his future business endeavors.

公司要感謝哈格里夫斯先生對公司發展的貢獻,並祝願他在未來的業務中取得圓滿成功。

About Cell MedX Corp. (OTC Pink: CMXC)

關於 Cell MedX Corp.(OTC Pink:CMXC)

Cell MedX Corp. is a biotech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to: aging, diabetes, high blood pressure, neuropathy and kidney function. The Company's main focus is on continued research and development of its eBalance Technology and its eBalance Home System.

Cell MedX Corp. 是一家生物技術公司,專注於治療和非治療產品的發現、開發和商業化,這些產品可促進整體健康,緩解與疾病相關的併發症,包括但不限於:衰老、糖尿病、高血壓、神經病和腎功能。該公司的主要重點是繼續研究和開發其eBalance技術和eBalance家庭系統。

On behalf of the Board of Directors of Cell MedX Corp.

代表 Cell MedX Corp. 董事會

David Jeffs
Director, CEO

大衛傑夫斯
董事、首席執行官

For further information:
info@cellmedx.com

欲了解更多信息:
info@cellmedx.com

Forward-Looking Statements

前瞻性陳述

The information included in this press release has not been reviewed by the FDA or Health Canada, nor has it been peer reviewed. This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects", "intends", "estimates", "projects", "anticipates", "believes", "could", and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company's Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should any of the Company's underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company's forward-looking statements. Except as required by law, Cell MedX Corp. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Cell MedX Corp. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.

本新聞稿中包含的信息未經美國食品藥品管理局或加拿大衛生部的審查,也沒有經過同行評審。本新聞稿包含前瞻性陳述。前瞻性陳述受風險、不確定性和假設的影響,以 “期望”、“打算”、“估計”、“項目”、“預期”、“相信”、“可能” 和其他類似詞彙來識別。所有涉及公司預期或預期未來將發生的產品性能、事件或發展的陳述均爲前瞻性陳述。由於這些陳述具有前瞻性,因此應根據重要的風險因素和不確定性對其進行評估,其中一些已在公司向美國證券交易委員會(“SEC”)提交的季度、年度和當前報告中進行了描述。如果其中一項或多項風險或不確定性得以實現,或者如果公司的任何基本假設被證明不正確,則實際業績可能與目前的預期存在重大差異。此外,不應過分依賴公司的前瞻性陳述。除非法律要求,否則Cell MedX Corp. 不承擔任何更新或公開宣佈對本新聞稿中包含的任何前瞻性陳述的任何修訂的義務。無法保證此類陳述會被證明是準確的,實際結果和未來事件可能與此類聲明中的預期存在重大差異。沒有證券交易所、證券委員會或其他監管機構對本新聞稿的充分性或準確性進行過審查,也不承擔任何責任。建議投資者仔細閱讀Cell MedX Corp. 不時向美國證券交易委員會提交的報告和文件,包括其年度、季度和當前報告。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論